New hope in the fight against cancer
Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.
Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.
Lancaster General Cancer Center participates in numerous studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group.
Lancaster General is a member of the University of Pennsylvania Cancer Center Network.
Current oncology treatment trials open for participation:
|
Site |
Sponsor |
Study Title |
|
Breast |
|
24-02 |
IBCSG |
A Phase III Trial evaluating the role of Ovarian Function Suppression and the role of Exemestane as Adjuvant Therapies for Premenopausal women with Endocrine responsive breast cancer ** Exemestane and Tamoxifen provided by Pharmacia* |
|
AVF4349n
VIRGO |
GENENTECH |
An Observational study of Treatment Patterns and Safety Outcomes for Metastatic or Local Recurrent Breast Cancer |
|
B-42 |
NSABP |
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer |
|
PACCT-1 |
ECOG |
Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial |
|
GI |
|
C80405 |
CALGB |
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum **Cetuximab provided** |
|
R-04 |
NSABP |
A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum |
|
GU |
|
E2804 |
ECOG |
E2804 -The Best Trial: A Randomized Phase II study of VEGF, RAF Kinase, mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, Temsirolimus in Advanced Renal Cell Carcinoma |
|
E2805 |
ECOG |
Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma |
|
Heme |
|
CML Registry |
NOVARTIS |
A Worldwide, Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients (The WORLD CML Registry) in routine practice |
|
E2905 |
ECOG |
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia |
|
Lung |
|
PrE0501 |
ALPHA Oncolgy |
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination with Docetaxel and Carboplatin ± Placebo or Maintenance Therapy with Vandetanib in Patients with IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)” |
|
Melanoma |
|
E1697 |
ECOG |
Phase III Randomized Study of Four Weeks High Dose IFN-"2b in Stage T3 - T4 or N1 (microscopic) Melanoma |
|
Myeloma |
|
E1A05 |
ECOG |
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade)-Lenalidomide (Revlimid)-Dexamethasone (VRD) versus Bortezomib (Velcade)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen |
|
S0777 |
SWOG |
Randomized Phase III trial of Lenalidomide and low dose dexamethasone (LDD) VS Bortezomab, Lenalidomide and low dose dexamethasone for induction in patients with previously untreated Multiple Myeloma without an intent for immediate autologous Stem Cell transplant |
Updated 11-2-2009.